Cytokinetics (CYTK) Income from Non-Controlling Interests (2013 - 2026)
Cytokinetics (CYTK) posted quarterly Income from Non-Controlling Interests of -$1.8 million for Q1 2026, down 239.74% year-over-year from $1.3 million in Q1 2025, and down 882.13% quarter-over-quarter from $235000.0 in Q4 2025.
Cytokinetics (CYTK) Income from Non-Controlling Interests (2013 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Income from Non-Controlling Interests for 14 consecutive years, with -$1.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests fell 239.74% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at -$2.3 million (down 205.49% YoY), while the FY2025 annual figure was -$990000.0, down 145.98% from the prior year.
- Income from Non-Controlling Interests slipped to -$1.8 million in Q1 2026 per CYTK's latest filing, from $235000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $6.5 million in Q3 2024 and bottomed at -$3.3 million in Q4 2024.
- Historically, Income from Non-Controlling Interests has averaged $12000.0 across 5 years, with a median of -$499000.0 in 2024.
- Annual changes were most pronounced in 2022 — Income from Non-Controlling Interests sank 2647.47% — and 2024, when it soared 1019.01%.
- Cytokinetics' Income from Non-Controlling Interests stood at $2.0 million in 2022, then slumped by 55.1% to $884000.0 in 2023, then slumped by 476.36% to -$3.3 million in 2024, then surged by 107.06% to $235000.0 in 2025, then slumped by 882.13% to -$1.8 million in 2026.
- Business Quant data shows CYTK's Income from Non-Controlling Interests at -$1.8 million in Q1 2026, $235000.0 in Q4 2025, and $167000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 63.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | -1.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.77 Mn |
| Mar 31, 2026 | -1.84 Mn |
| Dec 31, 2025 | 235,000.00 |
| Sep 30, 2025 | 167,000.00 |
| Jun 30, 2025 | -851,000.00 |
| Mar 31, 2025 | -541,000.00 |
| Dec 31, 2024 | -3.33 Mn |
| Sep 30, 2024 | 6.54 Mn |
| Jun 30, 2024 | -499,000.00 |
| Mar 31, 2024 | -556,000.00 |
| Dec 31, 2023 | 884,000.00 |
| Sep 30, 2023 | 584,000.00 |
| Jun 30, 2023 | 187,000.00 |
| Mar 31, 2023 | 1.95 Mn |
| Dec 31, 2022 | 1.97 Mn |
| Sep 30, 2022 | -1.07 Mn |
| Jun 30, 2022 | -905,000.00 |
| Mar 31, 2022 | -2.72 Mn |
| Dec 31, 2021 | -804,000.00 |
| Sep 30, 2021 | -43,000.00 |